Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Vector Borne Diseases

ClinicalTrials.gov lists 2,553 trials for Vector Borne Diseases or a narrower condition beneath it. National Institute of Allergy and Infectious Diseases (NIAID) has the most among industry and government lead sponsors, with 214.

MeSH D000079426 Infections C01
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 428 Phase 1/2 Phase 1/2 102 Phase 2 Phase 2 346 Phase 2/3 Phase 2/3 71 Phase 3 Phase 3 335 Phase 4 Phase 4 275 Not applicable Not applicable 443 Observational Observational 547 Phase 1 Phase 1 428 Phase 1/2 Phase 1/2 102 Phase 2 Phase 2 346 Phase 2/3 Phase 2/3 71 Phase 3 Phase 3 335 Phase 4 Phase 4 275 Not applicable Not applicable 443 Observational Observational 547

Trials per phase

2 more sections with rows

20 of the 2,553 trials are tagged with Vector Borne Diseases itself; the rest are tagged with a narrower condition beneath it.

Get the Vector Borne Diseases report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Vector Borne Diseases trials start? (33)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 10 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Unknown)

Top of scale: 149

1993: 2 trials (Observational 1, Phase 4 1) 1995: 3 trials (Observational 1, Not applicable 1, Phase 2 1) 1996: 1 trials (Observational 1) 1997: 2 trials (Phase 3 1, Phase 2 1) 1998: 5 trials (Observational 1, Not applicable 1, Phase 2/3 1, Phase 2 1, Phase 1 1) 1999: 5 trials (Not applicable 1, Phase 3 1, Phase 2 1, Phase 1 2) 2000: 6 trials (Observational 1, Not applicable 1, Phase 4 1, Phase 3 1, Phase 2 2) 2001: 16 trials (Observational 2, Not applicable 2, Phase 4 4, Phase 3 4, Phase 2 3, Phase 1/2 1) 2002: 33 trials (Observational 3, Not applicable 6, Phase 4 6, Phase 3 6, Phase 2/3 3, Phase 2 7, Phase 1/2 1, Phase 1 1) 2003: 41 trials (Observational 1, Not applicable 7, Phase 4 9, Phase 3 11, Phase 2/3 2, Phase 2 6, Phase 1/2 2, Phase 1 3) 2004: 60 trials (Observational 4, Not applicable 9, Phase 4 5, Phase 3 13, Phase 2/3 5, Phase 2 8, Phase 1/2 6, Phase 1 10) 2005: 88 trials (Observational 11, Not applicable 10, Phase 4 14, Phase 3 15, Phase 2/3 2, Phase 2 14, Phase 1/2 5, Phase 1 17) 2006: 108 trials (Observational 26, Not applicable 13, Phase 4 11, Phase 3 17, Phase 2 21, Phase 1/2 7, Phase 1 13) 2007: 95 trials (Observational 13, Not applicable 10, Phase 4 18, Phase 3 17, Phase 2/3 4, Phase 2 18, Phase 1/2 1, Phase 1 14) 2008: 78 trials (Observational 11, Not applicable 10, Phase 4 10, Phase 3 15, Phase 2/3 5, Phase 2 16, Phase 1/2 2, Phase 1 9) 2009: 96 trials (Observational 13, Not applicable 14, Phase 4 16, Phase 3 14, Phase 2/3 1, Phase 2 16, Phase 1/2 3, Phase 1 19) 2010: 120 trials (Observational 26, Not applicable 19, Phase 4 12, Phase 3 21, Phase 2/3 3, Phase 2 14, Phase 1/2 5, Phase 1 20) 2011: 107 trials (Observational 20, Not applicable 16, Phase 4 16, Phase 3 18, Phase 2/3 2, Phase 2 13, Phase 1/2 5, Phase 1 17) 2012: 98 trials (Observational 12, Not applicable 22, Phase 4 18, Phase 3 9, Phase 2/3 3, Phase 2 6, Phase 1/2 6, Phase 1 22) 2013: 97 trials (Observational 16, Not applicable 19, Phase 4 14, Phase 3 10, Phase 2/3 2, Phase 2 13, Phase 1/2 5, Phase 1 18) 2014: 111 trials (Observational 14, Not applicable 24, Phase 4 16, Phase 3 11, Phase 2/3 5, Phase 2 15, Phase 1/2 3, Phase 1 23) 2015: 112 trials (Observational 28, Not applicable 16, Phase 4 11, Phase 3 10, Phase 2/3 6, Phase 2 10, Phase 1/2 6, Phase 1 25) 2016: 149 trials (Observational 42, Not applicable 24, Phase 4 10, Phase 3 14, Phase 2/3 1, Phase 2 18, Phase 1/2 8, Phase 1 32) 2017: 98 trials (Observational 26, Not applicable 18, Phase 4 8, Phase 3 12, Phase 2/3 1, Phase 2 13, Phase 1/2 2, Phase 1 18) 2018: 115 trials (Observational 32, Not applicable 19, Phase 4 6, Phase 3 14, Phase 2 17, Phase 1/2 2, Phase 1 25) 2019: 112 trials (Observational 28, Not applicable 19, Phase 4 7, Phase 3 14, Phase 2/3 6, Phase 2 13, Phase 1/2 9, Phase 1 16) 2020: 94 trials (Observational 33, Not applicable 20, Phase 4 5, Phase 3 8, Phase 2/3 1, Phase 2 5, Phase 1/2 3, Phase 1 19) 2021: 134 trials (Observational 34, Not applicable 28, Phase 4 8, Phase 3 20, Phase 2/3 4, Phase 2 21, Phase 1/2 3, Phase 1 16) 2022: 117 trials (Other 2, Observational 27, Not applicable 23, Phase 4 11, Phase 3 13, Phase 2/3 2, Phase 2 17, Phase 1/2 3, Phase 1 19) 2023: 104 trials (Observational 32, Not applicable 23, Phase 4 8, Phase 3 5, Phase 2/3 3, Phase 2 9, Phase 1/2 6, Phase 1 18) 2024: 106 trials (Observational 32, Not applicable 24, Phase 4 10, Phase 3 11, Phase 2/3 2, Phase 2 12, Phase 1/2 3, Phase 1 12) 2025: 115 trials (Observational 30, Not applicable 24, Phase 4 10, Phase 3 13, Phase 2/3 2, Phase 2 15, Phase 1/2 3, Phase 1 18)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 90
2025 115
2024 106
2023 104
2022 117
2021 134
2020 94
2019 112
2018 115
2017 98

Showing 10 of 33 earlier years.

Start your 14-day trial Email me all 33 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 100 trials starting in 2026 and about 110 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 33 months from start to primary completion across 125 trials still running at the 2026-10-09 snapshot; registered median of 17 months across 1,762 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Vector Borne Diseases trials in? (10)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 428
Phase 1/2 102
Phase 2 346
Phase 2/3 71
Phase 3 335
Phase 4 275
Not applicable 443
Observational 547
Expanded access 4
Unknown 2

How many Vector Borne Diseases trials are recruiting? (11)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 80
Recruiting 157
Enrolling by invitation 8
Active, not recruiting 67
Available 1

Showing 5 of 11 statuses.

Start your 14-day trial Email me all 11 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Vector Borne Diseases trials? (8)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Institute of Allergy and Infectious Diseases (NIAID) 214
U.S. Army Medical Research and Development Command 82
GlaxoSmithKline 60
Sanofi Pasteur, a Sanofi Company 49
Pfizer 40

Showing 5 of 8 sponsors.

Start your 14-day trial Email me all 8 sponsors as a PDF

Which drugs are being tested for Vector Borne Diseases? (7)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Chloroquine 69
Primaquine 67
Tafenoquine 27
Yellow Fever Vaccine 26
Miltefosine 25

Showing 5 of 7 drugs.

Start your 14-day trial Email me all 7 drugs as a PDF

Interventions as named in the registry (8)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
1. Artemether-Lumefantrine (AL) 90
Dihydroartemisinine-Piperaquine 81
Pyrimethamine/sulfadoxine 47
Artesunate 38
PfSPZ (7G8) Challenge 28

Showing 5 of 8 interventions.

Start your 14-day trial Email me all 8 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Vector Borne Diseases trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Malaria 1,972 35
Pneumonia 1,924 66
Gastroenteritis 1,702 58
Anaemia 1,059 22
Febrile convulsion 1,056 29

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Vector Borne Diseases? (3)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Enhancing protection against vector-borne diseases in forcibly displaced communities: evaluating the efficacy of spatial repellents for cutaneous leishmaniasis control in North-East Syria. BMC medicine 2025 Yes
Efficacy of a spatial repellent for control of <i>Aedes</i>-borne virus transmission: A cluster-randomized trial in Iquitos, Peru. Proceedings of the National Academy of Sciences of the United States of America 2022 Yes
The use of drones for mosquito surveillance and control. Parasites & vectors 2022 Yes

Sub-conditions in MeSH (10)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages